My definition of risk is a potential unfavourable effect tha can be attributed to the clinical use of cel therapy which derived from monocyte. The monocyte will be cultured eg more than 4 days in growth factor and interleukin medium.
A monocyte based therapy would risk healing by fibrosis, if the disease involves tissue damaged areas. Within the circulation it could risk monokine release and damage as well.